Researchers trial inhalable gene therapy for cystic fibrosis, offering a potential breakthrough in treating the genetic lung ...

An inhalable medicine with the potential to improve lung disease in people with cystic fibrosis, irrespective of their ...

An inhaled gene therapy for cystic fibrosis developed by Boehringer Ingelheim is due to start clinical testing shortly, ...

A new inhalable gene therapy for cystic fibrosis (CF) has entered Phase I clinical trials, a major milestone on the journey ...

The global Cystic Fibrosis Market is valued at $10.4 billion in 2023 and is projected to reach $55.4 billion by 2032, ...

From life-altering genetic conditions to promising new treatments, here's what you need to know about 7 inherited diseases ...

An inhalable medicine with the potential to improve lung disease in people with cystic fibrosis is being tested in human ...

Hundreds of Lowcountry moms danced the night away all in support of research to support a treatment for a genetic disorder.

An inhalable medicine with the potential to improve lung disease in people with cystic fibrosis, irrespective of their mutation type, is being tested in human trials in the UK and Europe.

Boehringer Ingelheim, IP Group, the UK Respiratory Gene Therapy Consortium (GTC) 1 and OXB, 1 today announce the start of LENTICLAIR TM 1, a Phase I/II trial of BI 3720931, a novel, first-in-class, ...

Boehringer Ingelheim, the UK Respiratory Gene Therapy Consortium (GTC), IP Group and Oxford BioMedica (OXB) have commenced ...

Researchers at Imperial College London are leading human trials for the innovative treatmentAn inhalable medicine with the potential to improve lung ...